ArticleJAC-antimicrobial resistance2026
Contemporary multicentre analysis of carbapenemases distribution among clinical carbapenem-resistant Enterobacterales in Lebanon.
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Contemporary multicentre data on carbapenemase distribution among carbapenem-resistant Enterobacterales (CRE) in Lebanon remain limited. This study aimed to characterize the distribution of carbapenemase enzyme families among clinical CRE isolates collected from Lebanese hospitals. Methods: A multicentre study was conducted across 14 hospitals representing different Lebanese regions between March and October 2025. CRE isolates were centrally processed using standardized phenotypic microbiological methods and interpreted according to the 2025 European Committee on Antimicrobial Susceptibility Testing breakpoints. Carbapenemase identification was performed using NG-Test Results: A total of 59 non-duplicate CRE isolates from individual patients were included. New Delhi metallo-β-lactamase (NDM) was the predominant carbapenemase enzyme family (64.4%), followed by OXA-48-like enzymes (23.7%), with co-production observed in 10.2% of isolates. Among carbapenem-resistant Conclusions: NDM was the predominant carbapenemase among CRE isolates recovered from participating Lebanese hospitals, while Oxacillinase-48 carbapenemase (OXA-48)-like enzymes remained common. These findings highlight the importance of carbapenemase-specific characterization, as therapeutic options differ according to the underlying resistance mechanism. Rapid carbapenemase detection using NG-Test
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.